Merck Advances Oncology Portfolio and Pipeline with New and Long-term Data in Multiple Cancers at ESMO 2020

  • New analyses from Phase III JAVELIN Bladder 100 study of BAVENCIO®* assess efficacy across subgroups, patient-reported outcomes and exploratory biomarkers in advanced urothelial cancer
  • Overall efficacy data, and analyses of brain metastases and HRQoL for tepotinib from largest ongoing study in NSCLC harboring METex14 skipping
  • Long-term follow-up data for novel bifunctional fusion protein targeting TGF-β/PD-L1, bintrafusp alfa, in NSCLC and BTC demonstrate continued durability of response

Canada-based media” data-reactid=”16″Not intended for UK- US- or Canada-based media

Germany, Sept. 14, 2020 /PRNewswire/ — Merck, a leading science and technology company, today announced more than 30 abstracts will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 from September 19-21. The abstracts span the Company’s clinical program in oncology across several innovative modalities and mechanisms that have the potential to advance treatment

Read More